CTXRCitius Pharmaceuticals Inc
CTXR
Citius Pharmaceuticals Inc21,496
Mkt Cap
$19.11MVolume
98,582.0052W High
$2.4852W Low
$0.63PE Ratio
-0.30CTXR Fundamentals
Price
$0.8918Prev Close
$0.8542Open
$0.869950D MA
$0.7911Beta
1.44Avg. Volume
828,196.91EPS (Annual)
-$3.38P/B
0.24Rev/Employee
$0.00$21.26
Citius Oncology Provides Commercial Update on LYMPHIR Launch Highlighting Early Adoption and Expanding Clinical Development
Citius Oncology Provides Commercial Update on LYMPHIR Launch Highlighting Early Adoption and Expanding Clinical Development Citius Oncology Provides Commercial Update on LYMPHIR Launch Highlighting...
PR Newswire·6d ago
Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR in Discussions with Leading Cutaneous Lymphoma Experts
Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR in Discussions with Leading Cutaneous Lymphoma Experts Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR in Discussions with Leading Cutaneous Lymphoma Experts PR Newswire CRANFORD...
PR Newswire·13d ago
Citius Oncology Announces Positive Topline Results from InvestigatorInitiated Phase 1 Study of LYMPHIR in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers
Citius Oncology Announces Positive Topline Results from InvestigatorInitiated Phase 1 Study of LYMPHIR in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers Citius Oncology...
PR Newswire·27d ago
Citius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR (E7777) Dosing Prior to Commercial CART Therapy in HighRisk Diffuse Large BCell Lymphoma
Citius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR (E7777) Dosing Prior to Commercial CART Therapy in HighRisk Diffuse Large BCell Lymphoma Citius Oncology Announces...
PR Newswire·1mo ago
Citius Pharmaceuticals, Inc. Secures $3.8 million through New Jersey Economic Development Program
Citius Pharmaceuticals, Inc. Secures $3.8 million through New Jersey Economic Development Program Citius Pharmaceuticals, Inc. Secures $3.8 million through New Jersey Economic Development Program PR...
PR Newswire·1mo ago
Citius Pharmaceuticals Q1 Earnings Report: What Investors Need to Know
read more...
Benzinga·2mo ago
Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR
Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of...
PR Newswire·2mo ago
Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR
Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR PR Newswire...
PR Newswire·2mo ago
Citius Oncology Expands International Distribution of LYMPHIR to European Union Through Exclusive Agreement with Uniphar
Citius Oncology Expands International Distribution of LYMPHIR to European Union Through Exclusive Agreement with Uniphar Citius Oncology Expands International Distribution of LYMPHIR to European...
PR Newswire·2mo ago
Citius Pharmaceuticals (CTXR) Surges 22% After Hours Here's Why
Citius Pharmaceuticals shares jumped 22.12% after hours following the commercial launch of its LYMPHIR therapy and a fiscal 2025 business update.read more...
Benzinga·3mo ago
<
1
2
...
>